Loading...
Last submissions
-
-
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
-
-
-
Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩
-
P. Pautier, A. Floquet, C. Chevreau, N. Penel, C. Guillemet, et al.. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open, 2021, 6 (4), pp.100209. ⟨10.1016/j.esmoop.2021.100209⟩. ⟨hal-03623631⟩
-
Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, et al.. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer. JAMA oncology, 2023, pp.e231352. ⟨10.1001/jamaoncol.2023.1352⟩. ⟨hal-04117942⟩
-
-
Antonio Di Meglio, Julie Havas, Davide Soldato, Daniele Presti, Elise Martin, et al.. Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40 (10), pp.1111--1123. ⟨10.1200/JCO.21.01252⟩. ⟨hal-03855945⟩
-
Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, et al.. Prognostic significance of concurrent gene mutations i n intensively treated patients with IDH-mutated AML: an ALFA study. Blood, 2021, 137 (20), pp.2827-2837. ⟨10.1182/blood.2020010165⟩. ⟨hal-03604929⟩
-
-
Éric Leblanc, Fabrice Narducci, Gwénaël Ferron, Audrey Mailliez, Jean Yves Charvolin, et al.. Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study. Cancers, 2023, 15 (4), ⟨10.3390/cancers15041141⟩. ⟨hal-04068556⟩
-
-
Catherine Thieblemont, Loic Chartier, Ulrich Dührsen, Umberto Vitolo, Sally Barrington, et al.. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Advances, 2022, 6 (23), pp.5995-6004. ⟨10.1182/bloodadvances.2021006923⟩. ⟨inserm-03924551⟩
-
Rémy Duléry, Marie-Noëlle Lacassagne, Christine Giraud, Virginie Ader, Jean-Louis Beaumont, et al.. Mutualisation des outils de qualité pour les cellules CAR-T : recommandations de la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC). Bulletin du Cancer, 2020, 107, pp.S193 - S201. ⟨10.1016/j.bulcan.2020.10.001⟩. ⟨hal-03493426⟩
-
-
Steven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, Victoria Cacheux, Violaine Safar, et al.. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematology, 2020, 7 (11), pp.e798-e807. ⟨10.1016/S2352-3026(20)30291-X⟩. ⟨hal-03012903⟩
-
-
F. Derquin, A. Floquet, A.C. Hardy-Bessard, J. Edeline, J.P. Lotz, et al.. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecologic Oncology, 2020, 158 (3), pp.666-672. ⟨10.1016/j.ygyno.2020.06.491⟩. ⟨hal-02909552⟩
-
Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, et al.. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncology, 2019, 20, pp.1740 - 1749. ⟨10.1016/S1470-2045(19)30486-3⟩. ⟨hal-03489049⟩
Number of fulltext
86
Number of reference
401
Submissions evolution

Submissions distribution by document type
